Amifostine
Brand names: Ethyol · Active ingredient: Amifostine
In short: ETHYOL (amifostine) is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer . ETHYOL is indicated to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatm
What is Amifostine used for?
ETHYOL (amifostine) is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer
.
ETHYOL is indicated to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands
.
Limitation of Use
Do not use ETHYOL in other settings where chemotherapy can produce a significant survival benefit or cure
, or in patients receiving definitive radiotherapy
, except in the context of a clinical study.
Amifostine dosage
Hydration and Premedication
Prior to ETHYOL infusion, verify that patients are adequately hydrated and correct existing dehydration if clinically indicated.
When administering ETHYOL at the 910 mg/m
2dose, antiemetic medications, including intravenous dexamethasone 20 mg and a serotonin 5HT
3receptor antagonist, are recommended prior to ETHYOL administration. Additional antiemetics may be required based on the chemotherapy drugs administered.
When administering ETHYOL at the 200 mg/m
2dose, it is recommended that antiemetic medication be administered prior to ETHYOL administration. Oral 5HT
3receptor antagonists, alone or in combination with other antiemetics are recommended in the radiotherapy setting.
Supine Position and Blood Pressure Monitoring
Patients should be kept in a supine position during the ETHYOL infusion.
When administering ETHYOL at the 910 mg/m
2dose, monitor blood pressure before, at least every 5 minutes during the infusion, at the end of the infusion, and thereafter as clinically indicated.
When administering ETHYOL at the 200 mg/m
2dose, monitor blood pressure before and at the end of the infusion, and thereafter as clinically indicated.
The recommended starting dose of ETHYOL is 910 mg/m
2administered as a 15-minute intravenous infusion, starting 30 minutes prior to chemotherapy. Do not exceed a 15-minute infusion time due to the increased risk of infusion-related reactions. The use of less than 15-minute infusion times for ETHYOL use with chemotherapy have not been established.
The recommended dose of ETHYOL is 200 mg/m
2administered as a 3-minute intravenous infusion, starting 15-30 minutes prior to standard fraction radiation therapy (1.8-2.0 Gy).
The infusion of ETHYOL should be interrupted if the systolic blood pressure decreases significantly from the baseline value as listed in Table 1.
If severe infusion-related reactions occur, immediately and permanently discontinue ETHYOL.
Baseline Systolic Blood Pressure(mm Hg)
<100 | 100-119 | 120-139 | 140-179 | ≥180
Decrease in systolic blood pressure during infusion of ETHYOL (mm Hg) | 20 | 25 | 30 | 40 | 50
If the blood pressure returns to normal within 5 minutes and the patient is asymptomatic, the infusion may be restarted so that the full dose of ETHYOL may be administered.
When administering ETHYOL at the 910 mg/m
2dose, if the full dose of ETHYOL cannot be administered, the dose of ETHYOL for subsequent chemotherapy cycles should be 740 mg/m
2.
Reconstitution
During reconstitution of ETHYOL, the use of gloves is recommended, and avoid contact with the skin or mucous membranes. Follow special handling and disposal procedures
.
A vial of ETHYOL may contain more drug than is required for the recommended dose or multiple vials may be needed to obtain the recommended dose. …
How to take Amifostine — instructions & advice from the label
Hypotension and Cardiovascular Events
Inform the patient that he or she may experience hypotension after ETHYOL infusion
. Advise the patient to inform the prescriber if he or she is receiving anti-hypertensive medications or other drugs that could cause or potentiate hypotension
.
Severe Cutaneous Reactions
Inform the patient that severe cutaneous reactions may develop during or weeks after initiation of ETHYOL administration. Advise the patient to inform the prescriber if they experience any cutaneous reactions or mucosal lesions outside of the injection site or radiation port, or on the palms or soles, as discontinuation of the drug may be necessary
.
Hypersensitivity
Inform the patient that he or she may experience allergic reactions after ETHYOL infusion
. ETHYOL might need to be discontinued for severe acute allergic reactions and the patient receive other treatments
.
Nausea and Vomiting
Inform the patient that he or she may experience severe nausea and/or vomiting after ETHYOL infusion
.
Hypocalcemia
Inform the patient that calcium supplements may be necessary if hypocalcemia is identified
. Blood tests may be needed to identify this, and correct the condition. …
Warnings & precautions
Do not take this medicine if: ETHYOL is contraindicated in patients with known hypersensitivity to aminothiol compounds.
ETHYOL may interfere with the antitumor activity of chemotherapy regimens. Do not use ETHYOL in patients receiving chemotherapy for other malignancies in which chemotherapy can produce a significant survival benefit or cure (e.g., certain malignancies of germ cell origin), except in the context of a clinical study. Limited data are currently available regarding interference with antitumor efficacy when ETHYOL is administered prior to cisplatin therapy in settings other than advanced ovarian cancer.
ETHYOL may interfere with the antitumor activity of the radiotherapy regimens. Do not use ETHYOL in patients receiving definitive radiotherapy, except in the context of a clinical trial, since there are insufficient data to exclude a tumor-protective effect in this setting. ETHYOL was studied with standard fractionated radiotherapy and when ≥75% of both parotid glands were exposed to radiation. The safety and efficacy of ETHYOL on the incidence of xerostomia in the setting of combined chemotherapy and radiotherapy, and in the setting of accelerated or hyperfractionated therapy, have not been established.
Severe hypotension with serious sequelae have been reported in clinical studies and post-marketing experience in patients treated with ETHYOL.
Severe hypotension events included apnea, dyspnea, hypoxia, chest pain, tachycardia, bradycardia, extrasystoles, supraventricular tachycardia, atrial fibrillation/flutter, myocardial ischemia, myocardial infarction, unconsciousness, syncope, seizure, renal failure, and respiratory and
cardiac arrest.
In the WR-1 study of patients with ovarian cancer dosing ETHYOL at 910 mg/m
2, transient hypotension was observed in 62% of the patients
treated, with 8% of the patients experiencing ≥ Grade 3 hypotension. …
Amifostine side effects
The following serious adverse reactions are discussed in greater detail in other sections of the labeling:
– Hypotension and Cardiovascular Events
– Severe Cutaneous Reactions
– Hypersensitivity
– Nausea and Vomiting
– Hypocalcemia
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
ETHYOL was administered to patients receiving chemotherapeutic agents for advanced ovarian cancer (WR-1 study) or who were receiving standard fractionated radiotherapy for head and neck cancer (WR-38 study)
.
In the WR-38 study of patients with head and neck cancer, 17% (26/150) discontinued ETHYOL due to adverse reactions. All but one of these patients continued to receive radiation treatment until completion.
Table 2 summarizes adverse reactions reported in patients from the WR-1 and WR-38 clinical trials. …
Drug interactions
Closely monitor patients receiving anti-hypertensive medications or other drugs that could cause or potentiate hypotension.
About this medicine
ETHYOL (amifostine) is an organic thiophosphate cytoprotective agent known chemically as 2-[(3-aminopropyl)amino]ethanethiol dihydrogen phosphate (ester) and has the following structural formula:
Amifostine is a white crystalline powder which is freely soluble in water. Its empirical formula is C
5H
15N
2O
3PS and it has a molecular weight of 214.22.
ETHYOL is the trihydrate form of amifostine and is supplied as a sterile lyophilized powder requiring reconstitution for intravenous infusion. Each single-dose 10 mL vial contains 500 mg of amifostine on the anhydrous basis.
How it works: ETHYOL is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to a pharmacologically active free thiol metabolite. This metabolite is believed to be responsible for the reduction of the cumulative renal toxicity of cisplatin and for the reduction of the toxic effects of radiation on normal oral tissues. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID a17563f2-d231-4385-bc94-0217be78b89d. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate